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Abstract: Lipid rafts and caveolae are microdomains of the plasma membrane enriched in sphingolipids and cholesterol, 
and hence are less fluid than the remainder of the membrane. Caveolae have an invaginated structure, while lipid rafts are 
flat regions of the membrane. The two types of microdomains have different protein compositions (growth factor recep-
tors and their downstream molecules) suggesting that lipid rafts and caveolae have a role in the regulation of signaling by 
these receptors. The purpose of this review is to discuss this model, and the implications that it might have regarding a po-
tential role for lipid rafts and caveolae in human cancer. Particular attention will be paid to the epidermal growth factor 
receptor, for which the largest amount of information is available. It has been proposed that caveolins act as tumor sup-
pressors. The role of lipid rafts is less clear, but they seem to be capable of acting as ‘signaling platforms’, in which signal 
initiation and propagation can occur efficiently. 
INTRODUCTION 
  The ‘fluid mosaic’ model envisions the plasma mem-
brane to contain proteins floating freely in a uniform ‘sea’ of 
lipid. However, the plasma membrane is no longer thought 
of as a uniform structure, following the identification of mic-
rodomains known as lipid rafts and caveolae. These micro-
domains are of a less fluid character than the remainder of 
the membrane, and are enriched in certain proteins, in par-
ticular those involved in signal transduction. This has led to 
the hypothesis that they might act as membrane signalling 
platforms. The aim of this article is to discuss the possible 
role that these membrane microdomains play in growth fac-
tor receptor signal transduction. We will therefore begin by 
describing the structure of lipid rafts and caveolae and the 
proteins that are targeted to these domains, before going on 
to discuss in detail their possible roles in the signalling of 
certain growth factor receptors. Lastly, we will discuss how 
the alteration of signalling in these microdomains may lead 
to cancer in humans. 
CAVEOLAE 
  Caveolae were first described in the 1950s as 50-100 nm 
flask-shaped invaginations of the plasma membrane [1] (Fig. 
1A). Caveolae have been found to be insoluble in non-ionic 
detergents such as Triton X-100, and this property has been 
used to purify and characterise these domains. Following 
treatment with detergent at 4ºC, these insoluble domains are 
then separated from the remainder of the cell membrane by 
ultracentrifugation in a sucrose density gradient [2]. Alterna-
tively, a detergent-free fractionation procedure can be used, 
following which caveolae are present in low buoyant density  
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fractions [3]. The insolubility of caveolae in detergent is 
thought to be due to an enrichment in sphingolipids and cho-
lesterol [4, 5], as opposed to the majority of the cell mem-
brane, which is composed mainly of glycerophospholipids. 
Unsaturated acyl chains are common in the latter, while 
sphingolipids contain largely saturated chains, allowing them 
to pack together more tightly. Hence, glycerophospholipids 
exist in a loosely packed, liquid-disordered phase (the liquid 
crystalline, lc phase). In the absence of cholesterol, sphin-
golipids form a very solid phase known as the gel phase; 
however, in caveolae cholesterol is present, and this causes 
these domains to exist in a new phase, the liquid-ordered 
phase (lo) [6]. In this phase the lipids are still tightly packed, 
but also have a high degree of lateral mobility. These proper-
ties confer insolubility in non-ionic detergents, and depletion 
of these domains of either sphingolipids or cholesterol in-
creases their solubility in Triton X-100 [7]. 
  Caveolae possess a striated coat on their cytoplasmic 
face, major components of which are proteins known as 
caveolins. There are now three known members of the cave-
olin gene family: caveolin-1 (two isoforms  and ) [8, 9], 
caveolin-2 (three isoforms ,   and ) [10] and caveolin-3 
[11]. The N- and C-termini of caveolins are cytoplasmic, 
suggesting that they form a ‘hairpin’ structure in the mem-
brane (Fig. 1A), and they are palmitoylated on several resi-
dues [12]. Caveolins –1 and –2 have a wide, overlapping 
distribution: they (and therefore caveolae) are present in 
most cell types, being most abundant in endothelial cells, 
fibroblasts, adipocytes, pneumocytes and epithelial cells [13, 
14]. In contrast, caveolin-3 is almost solely expressed in 
smooth and skeletal muscle [15]. 
  Two forms of caveolae, ‘deep’ and ‘shallow’, have been 
identified, with different distribution of the three caveolins 
and the respective isoforms [10, 16]. It is possible that these 
domains have functional differences, but this has not been 
sufficiently studied. Caveolins are thought to be an important 
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to the ability of caveolin to bind cholesterol [17] and sphin-
golipids [18]. More precisely caveolin-1 or caveolin-3 re-
expression in cells lacking both caveolae and caveolin ex-
pression induces caveolae formation and reconstitutes the 
caveolar coat [19]. However, expression of caveolin-2 alone 
doesn’t lead to caveolae formation, but requires co-
transfection of caveolin-1 [19, 20] Caveolins are phosphory-
lated on Ser/Thr sites by PKC and on Tyr by Src and possi-
bly other tyrosine kinases [21]. 
  The number of caveolae in a cell and the level of caveo-
lin expression are also intimately linked to the concentration 
of cholesterol. Increasing the level of free cholesterol in fib-
roblasts by increasing the external concentration of low den-
sity lipoprotein (LDL) led to an upregulation of caveolin 
mRNA and increased the number of caveolae [22], while 
depleting cholesterol using cholesterol-sequestering agents 
led to a decrease in caveolin mRNA levels [23]. In turn, de-
creasing caveolin concentration lowered the rate of choles-
terol efflux from the cells, suggesting that caveolae are in-
volved in cholesterol homeostasis [22]. 
  In addition to caveolins, another family of proteins has 
been shown to form an integral component of caveolae. 
These are the flotillins, flotillin-1 and flotillin-2 (epidermal 
surface antigen) [24]. Flotillins can form hetero-oligomeric 
complexes with caveolins, and are probably structural com-
ponents, which participate in the formation of caveolae [25]. 
LIPID RAFTS 
  The discovery that detergent-insoluble domains were 
present in cells lacking caveolae and caveolins [26, 27] sug-
gested that membrane microdomains distinct from caveolae 
might exist. These domains can also co-exist with caveolae 
in the same cell, and can be isolated separately [28] and are 
present in the same membrane fractions as caveolin, using 
detergent-dependent or –independent methods. They have 
been coined ‘lipid rafts’ [29], and have an estimated diame-
ter of less than 70 nm [30], possibly being as little as 26+/-
13nm [31]. Like caveolae, they are enriched in spingolipids 
and cholesterol, but do not seem to form any particular struc-
ture as caveolae do, rather being flat regions of the cell 
membrane that exist in the liquid ordered phase (Fig. 1B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Structure of lipid rafts and caveolae. A) Caveolae; B) Lipid Rafts. Caveolin molecules in (A) are shown as hairpin-shaped struc-
tures in the inner leaflet; N- and C-termini project into the cytoplasm. GPI-anchored proteins are anchored on the outer leaflet of caveolae 
and lipid rafts, while signalling molecules such as Src kinase associate with the inner leaflet.  14    The Open Biochemistry Journal, 2007, Volume 1  de Laurentiis et al. 
Unlike caveolae, they are probably found ubiquitously, while 
caveolae are excluded from certain cells, such as T lympho-
cytes [32]. 
  There have been concerns that lipid rafts might be arte-
facts arising from the treatment of membranes with detergent 
at low temperature [33]. Firstly, treatment with Triton X-100 
is usually performed at 4ºC, and the cooling of the mem-
brane by itself promotes the formation of the liquid ordered 
phase [6]. In addition, Triton X-100 was shown to promote 
the formation of liquid-ordered domains when added to an 
originally homogeneous membrane [34]. Despite these ob-
servations, there is evidence that lipid rafts exist in the liquid 
ordered phase prior to addition of detergent. Ahmed et al. [5] 
used a detergent-free, fluorescence quenching technique to 
show that phase separation did occur in membranes with a 
similar composition to the plasma membrane, suggesting the 
co-existence of a liquid-ordered phase containing sphingo-
lipids and cholesterol, and a liquid crystalline phase. Phase 
separation occurred at 37ºC, and was promoted by choles-
terol. Furthermore, the degree of insolubility in Triton X-100 
correlated with the proportion of the membrane that was in 
the liquid-ordered phase. This suggests that these domains 
are probably present before detergent extraction; however it 
must still be noted that detergent probably alters the proper-
ties of these domains and their interaction with certain pro-
teins, and that results obtained following treatment of mem-
branes with detergent must be treated with caution. The de-
tergent method certainly cannot be used to determine the 
difference between lipid rafts and caveolae when both these 
domains are present in the same cell. 
  Other lines of evidence also support the existence of lipid 
rafts in cell membranes [35]. For example, Varma and 
Mayor [30] used fluorescence resonance energy transfer 
(FRET) to show that glycosylphosphatidylinositol (GPI)-
anchored folate receptors attached to a fluorescent folic acid 
analogue were clustered in domains of a size less than 70 
nm. Depleting the cell membrane of cholesterol resulted in a 
decreased FRET efficiency, consistent with an increased 
distance between folate receptors. Addition of cholesterol to 
the cell resulted in restoration of the proteins to ordered do-
mains. These results have been taken as proof of the exis-
tence of cholesterol-rich microdomains into which these pro-
teins cluster. This hypothesis is further supported by work by 
Friedrichson and Kurzchalia [36], who used chemical cross-
linking to demonstrate that GPI-anchored proteins were clus-
tered at the plasma membrane, and that depletion of choles-
terol decreased clustering, whereas addition of cholesterol 
increased the size of the clusters. The strongest evidence for 
non-caveolae nanodomains (50–200 nm in dimension in the 
outer leaflet of the plasma membrane) comes from immu-
nogold electron microscopy of components of, for example, 
the T cell receptor (TCR)
 in fixed cells, where labelled pro-
teins are detected in clusters [35]. 
  Since lipid rafts are small and transient, the biophysical 
challenges of measuring them are still great. Indeed, the 
most controversial area of membrane lateral organization is 
on the nanoscale level, where technology with sufficient 
simultaneous spatial and temporal resolution is not yet avail-
able. Refining existing methods and developing new ones to 
study lipid rafts is now required for progress, with the goal 
of studying dynamic membrane structure in living cells [35]. 
The applicable techniques, for the most part, rely on fluores-
cence microscopy because of high sensitivity and applicabi-
lity to single, living cells. Several techniques with the poten-
tial to most directly detect and characterize lipid rafts in liv-
ing cells were reviewed recently [35]. 
  Interestingly, it has been shown that flotillin-1 and flo-
tillin-2 (also known as reggie-2 and –1) are localised in lipid 
rafts [37] and co-localise with GPI-anchored cell adhesion 
molecules, known to be found in rafts. It is necessary to note 
here that, although the outer leaflet of lipid rafts (Fig. 1) is 
thought to be composed of sphingolipids and cholesterol, the 
nature of the inner leaflet in unknown. 
PROTEINS ASSOCIATED WITH LIPID RAFTS AND 
CAVEOLAE 
  Besides the caveolins and flotillins, numerous other pro-
teins have been associated with lipid rafts and caveolae. As 
mentioned above, there is evidence for the clustering of GPI-
anchored proteins in lipid rafts, and they have also been 
identified in caveolae [38]. The existence of different func-
tional GPI anchors as well as the fact that different rafts 
show markedly different lipid and protein profiles implies 
the presence of heterogeneous group of anchors and corres-
ponding rafts [39, 40]. 
  In addition, many proteins associated with the microdo-
mains are receptors or proteins involved in signal transduc-
tion. These include G protein -subunits, which have been 
shown to bind to caveolin in vitro [41]. A later study showed 
that different G protein subtypes localised preferentially to 
particular microdomains [42]. Several G-protein-coupled 
receptors have also been localised to membrane microdo-
mains; some of these only become localised to these do-
mains upon activation – for example the muscarinic acetyl 
choline receptor in caveolae [43]. Interestingly, a down-
stream component of signalling by this receptor, endothelial 
nitric oxide synthase, is localised to caveolae, and is thought 
to be negatively regulated by caveolin [44]. 
  A number of other proteins that are able to interact with 
caveolin localise to caveolae. A detergent-free method, 
which gives a more accurate view of the proteins associated 
with rafts/caveolae than the detergent method [45], was used 
to demonstrate the co-fractionation of caveolin with H-Ras 
[46], c-Src, cdc42, Rho, Lyn and Fyn [47]. Ras was found to 
interact with caveolin, although a mutationally activated 
form of Ras would not bind to caveolin [48]. Furthermore, 
another study showed that caveolin binds to c-Src, although 
it will not bind mutationally-activated v-Src [49]. In addi-
tion, binding of caveolin-1 or caveolin-3 inhibited the auto-
phosphorylation and activation of c-Src and the related Src-
family tyrosine kinase Fyn [49]. These interactions were 
mediated by residues 82-101 in the cytoplasmic N-terminus 
of caveolin-1, a region of the protein which is called the 
‘scaffolding domain’, and which interacts with numerous 
proteins. Furthermore, it has been described that caveolin 
phosphorylated on Tyr 14 can inhibit Src through the re-
cruitment of c-terminal src kinase (Csk). The scaffolding 
domain of caveolin-1 seems also to be responsable for fur-
ther interactions, since it contains a motif conserved in gua-
nine nucleotide dissociation inhibitors (GDIs) which sug-
gested a novel role for caveolin-1. Nevins and Thurmond 
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[50]. Further studies also revealed a role in the activation and 
regulation of Rho, suggesting a role of caveolin-1 in cell 
polarity and migration [51]. del Pozo et al. [52] reported that 
lipid rafts are involved in signal transduction events initiated 
by cell adhesion to the extracellular matrix, which is medi-
ated by integrins. They reported that lipid rafts are controlled 
by integrins to target Rho and Rac GTPases to specific 
plasma membrane domains and to couple them to their 
downstream effector molecules [53-55]. 
  A detergent-free method was used to demonstrate the lo-
calisation of a number of proteins including Ras, the adapter 
protein Grb2, Erk2 (extracellular signal-regulated kinase 2) 
and the tyrosine kinases Fyn, TrkB (tyrosine kinase receptor 
B) and nerve growth factor (NGF) receptor (TrkA) in low 
buoyant density domains lacking caveolin-1 [56]. Lipid rafts 
have also been associated with signalling molecules in lym-
phocytes, which do not contain caveolin. For example, the T-
cell receptor has been located in detergent-insoluble rafts fol-
lowing its activation, as have the signalling molecules Shc, 
Ras, Syk, and the Src kinases Lck and Fyn [32, 57, 58]. It 
must however be noted that these two studies utilised the de-
tergent extraction method, and it has been shown that proteins 
associated with rafts and caveolae can be differentially soluble 
in different detergents [59], possibly due to a difference in 
their interactions with rafts/caveolae or due to the presence of 
distinct types of raft [60]. Therefore the detergent extraction 
method does not give an accurate view of all the proteins pre-
sent in rafts. Finally, recent studies suggest that the differential 
localization of rafts is important in the control of cell migra-
tion [61, 62]. 
 Table  1 summarises the proteins and lipid species found 
in lipid rafts and caveolae. This is not an all inclusive list but 
contains many of the proteins and lipids relevant to this dis-
cussion. What causes these proteins to target to lipid rafts 
and caveolae? Melkonian et al. [63] hypothesised that this 
might depend on the lipid modification of the proteins and 
their affinity for the liquid-ordered phase. Acyl chains, such 
as myristate and palmitate, and those found in GPI-anchored 
proteins, are saturated and likely to partition into liquid-
ordered domains, while, for example, prenyl chains are bulk-
ier and less likely to favour this phase. Melkonian et al. [63] 
showed that detergent-insoluble membranes were indeed 
enriched in palmitoylated proteins, although not all palmi-
toylated proteins in the cell were targeted to these domains. 
In contrast, prenylated proteins were excluded from the do-
mains. In a later study, Zacharias et al. [64] produced similar 
results using a detergent-free method. They used FRET bet-
ween two variants of green fluorescent protein: cyan fluores-
cent protein (CFP) and yellow fluorescent protein (YFP), 
which had been mutated so that they were unable to dimer-
ize. Attaching myristoyl and palmitoyl chains to CFP and 
YFP caused them to form clusters in the membrane, and this 
was disrupted by depleting cholesterol. In addition, they 
were shown to cluster with caveolin. However, while preny-
lated fluorescent proteins were seen to cluster, this was not 
disrupted by cholesterol depletion. They also detected acy-
lated, but not prenylated fluorescent proteins in detergent-
insoluble fractions. Taken together, the results of these two 
studies do indicate that acylated proteins are more likely to 
be targeted to lipid rafts and caveolae; however, the prenyl 
chain used by Zacharias et al. [64] is not truly representative 
Table 1.  Lipids and Proteins Targeted to Lipid Rafts and Caveolae 
 
Lipid Rafts  Caveolae  Ref. 
Lipid components:  
Cholesterol 
Sphingomyelin 
Glyco-sphingolipid 
Phosphatidylinositol 4,5-bisphosphate 
Ganglioside GM1 
Ganglioside GM3 
Lipid components: 
Cholesterol 
Sphingomyelin 
Glyco-sphingolipid 
Phosphatidylinositol 4,5-bisphosphate 
Ganglioside GM1 
 
[90, 115, 209, 210, 211, 212] 
Structural proteins: 
Flotillin-1 and -2 
Structural proteins: 
Flotillin-1 and –2 
Caveolin-1, -2 and –3 
 
[9, 10, 11, 24, 213] 
Signalling proteins: 
H-Ras 
Gi, Go, G 
Src kinases 
Syk kinase 
Grb2, Erk2 
Shc 
Signalling proteins: 
H-Ras 
Gq 
Src kinases 
eNOS 
Phosphatidylinositol 3-kinase 
Phospholipase C 
 
 [32, 42, 48, 49, 56, 57, 115, 160, 214] 
Receptors: 
PDGF receptor 
EGF receptor 
IGF-1 receptor 
TrkA, TrkB 
Receptors: 
PDGF receptor 
EGF receptor 
IGF-1 receptor 
TrkA 
CD36 
 
 [56, 96, 115, 128, 136, 137, 215] 
GPI-Anchored proteins: 
e.g. CD59 
 
uPAR 
 
 [216, 217] 
EGF: epidermal growth factor; eNOS: endothelial nitric oxide synthase; Erk: extracellular signal-regulated kinase; IGF: insulin-like growth factor; PDGF: platelet-derived growth 
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of those found in the cell [65], and so the exclusion of preny-
lated proteins is not conclusive. 
ROLE OF LIPID RAFTS AND CAVEOLAE IN SIG-
NALLING BY GROWTH FACTOR RECEPTORS 
  The role of lipid rafts and caveolae in signalling by sev-
eral growth factor receptors has been studied, but none more 
so than the epidermal growth factor receptor (EGFR). We 
will therefore be paying particular attention to this receptor. 
However, we will also discuss several other receptors for 
which information is sparser. 
1) Epidermal Growth Factor Receptor (EGFR) 
Structure and Function of the EGFR 
  The epidermal growth factor receptor (EGFR) signaling 
pathway
 is an important mediator of cancer cell oncogenesis, 
proliferation,
 maintenance, and survival [66]. This receptor is 
expressed in all epidermal and stromal cells as well as some 
glial and smooth muscle cells, and has several ligands, in-
cluding EGF itself, transforming growth factor (TGF)-, and 
heparin-binding EGF (HB-EGF) [66]. It can also be transac-
tivated by the binding of ligands to certain G-protein coupled 
receptors, such as the angiotensin II receptor [67]. The 
EGFR has three known homologues: ErbB2 (Neu or HER2), 
ErbB3 (HER3) and ErbB4 (HER4), with which it can form 
heterodimers [68]. Ligand binding causes homo- or hetero-
dimerization of the receptor and activates its tyrosine kinase 
activity, allowing it both to autophosphorylate and to phos-
phorylate downstream signalling molecules [69]. The EGFR 
consists of a number of extracellular domains forming the 
ligand-binding site [68]. There is then a transmembrane se-
quence and juxtamembrane domain, followed by an intracel-
lular kinase domain and C-terminal domain. Five autophos-
phorylation motifs are found in the C-terminal domain, pro-
viding docking sites for proteins containing SH2 (Src ho-
mology region 2) and phospho-tyrosine binding (PTB) do-
mains (e.g., Grb2). The C-terminus can also act as an auto-
inhibitory domain when not phosphorylated [66]. Nine phos-
phorylation sites were described in the EGFR, which differen-
tially regulate the activation of downstream signalling path-
ways [70, 71]. Firstly there is the well-characterised p42/44 
mitogen-activated protein kinase (MAPK) pathway. This 
begins with the recruitment of Grb2, which contains an SH2 
domain and can bind either directly to the phosphorylated 
EGFR, or to Shc, an adapter protein that becomes associated 
with and tyrosine phosphorylated by the EGFR. Grb2 is as-
sociated with SOS, a Ras guanine nucleotide exchange fac-
tor, which is then able to activate membrane-associated Ras 
[68]. Ras is activated by the exchange of its associated GDP 
with GTP, and in turn activates Raf-1, a serine/threonine 
kinase, which leads to the activation of the MAPK pathway. 
This involves the phosphorylation of MEK (MAP kinase 
kinase) and the activation and translocation of Erk1 and Erk2 
to the nucleus, where they phosphorylate transcription fac-
tors such as Elk, stimulating cell proliferation and motility. 
  Other targets of the EGFR include phospholipase C 
(PLC), phospholipase D (PLD)-1 and –2, and phosphatidy-
linositol-3-kinase (PI3K). PLC hydrolyses phosphatidyli-
nositol-4,5-bisphosphate (PIP2) to produce diacylglycerol 
and inositol 1,3,5,-trisphosphate (IP3), the latter of which 
releases calcium from intracellular stores. This results in the 
activation of many calcium-dependent enzymes and down-
stream pathways [68]. PLC can also mobilise actin modify-
ing proteins, enhancing cell motility [66]. PLD-1 may be 
activated via protein kinase C [72], while PLD-2 can be 
activated directly by the EGFR [68]. PLD hydrolyses phos-
phatidylcholine to produce choline and phosphatidic acid 
(PA) (Fig. 2). PA in turn activates mTOR (mammalian target 
of rapamycin), with which it directly interacts [73]. Among 
other things, mTOR activates the ribosomal protein S6 
kinase 1 (S6K1), which phosphorylates the ribosomal S6 
protein, leading to increased cell growth (Fig. 2). PI3K 
phosphorylates PIP2 to produce phosphatidylinositol-3,4,5,-
trisphosphate (PIP3), which can be converted to phosphatidy-
linositol-3,4-bisphosphate (PI(3,4)P2) by SH2-containing 
inositol-5-phosphatase (SHIP) [74, 75] (Fig. 2). PIP3 and 
PI(3,4)P2 stimulate the activity the serine/threonine kinase 
Akt (also known as protein kinase B) by binding to its Pleck-
strin Homology (PH) domain. Also required for activation of 
Akt is its phosphorylation on threonine 308, which occurs 
via  phosphoinositide-dependent kinase-1 (PDK1), an en-
zyme activated by PIP3 (Fig. 2). PDK1 can also activate S6K 
[76]. Phosphorylation on serine 473 is controlled by the ric-
tor-mTOR complex [77]. It is of interest to note here that a 
lipid raft-associated Akt Ser473 kinase was described [78], 
and subsequently shown to be DNA-dependent protein 
kinase (DNA-PK) [79]. This enzyme may also be involved 
in the regulation of Akt under specific conditions. Akt can 
phosphorylate proteins such as CREB (cAMP response ele-
ment binding protein), pro-caspase-9, BAD and the forkhead 
family of transcription factors (FKHR), and is involved in 
the regulation of apoptosis, gene expression and cell prolife-
ration [74]. 
  Finally, the activation of Src kinases is associated with 
activation of the EGFR. Src kinases have numerous sub-
strates, including PI3K and elements of the cytoskeleton 
[68]. 
Role of Lipid Rafts and Caveolae in Signalling by the 
EGFR 
  The involvement of lipid rafts and caveolae in signalling 
by the EGF receptor (EGFR) is by no means clear cut. In-
deed, there is a great deal of discrepancy in the literature, due 
in the most part to the use by some researchers of methods 
which do not allow exclusive separation of lipid rafts and 
caveolae. 
Evidence for EGFR Signalling within Caveolae 
 Mineo  et al. [80] used a detergent-free fractionation 
method to isolate low buoyant density, caveolin-rich mem-
brane fractions from Rat-1 cells, some of which had been 
treated with EGF. H-Ras, Grb2 and SOS-1 were concen-
trated in the caveolin-rich fraction, both in unstimulated cells 
and in those that had been exposed to EGF. On the other 
hand, they found that Raf-1 was only present in the caveolin 
fraction following stimulation by EGF, but that this Raf-1 
was active. Conversely, the EGFR was present in the caveo-
lin fraction in unstimulated cells, but its levels began to de-
cline after 30 seconds’ stimulation by EGF, and following 60 
minutes’ stimulation it was no longer detectable in this frac-
tion. These results were taken to indicate that EGFRs were 
present in caveolae, causing them to cluster and therefore 
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tion, the EGFR would migrate out of caveolae, allowing 
termination of the response. Mineo et al. [81] obtained simi-
lar results for the EGFR, showing that before activation, 
60.5% of EGFRs were present in the caveolin fraction of 
human fibroblasts, but there was a dramatic decrease in 
number following EGF application. 
 Jang  et al. [82] also localised the EGFR in caveolin-rich 
membrane fractions in unstimulated cells (in this case, A431 
and COS-7 cells). Following treatment with EGF, phosphol-
ipase C (PLC) was recruited to the caveolin fraction. They 
also used immunostaining of COS-7 cells to visualise the 
recruitment of PLC to the membrane: following EGF stimu-
lation, labelled PLC was shown to co-localise with caveo-
lin. In addition, depletion of cellular cholesterol resulted in 
translocation of the EGFR and caveolin-1 out of the low 
buoyant density fraction and prevented recruitment of PKC 
to this fraction, as well as inhibiting PIP2 turnover. However, 
PLC phosphorylation by the EGFR was not decreased upon 
cholesterol depletion, suggesting that the EGFR can still 
activate PLC when it is delocalised from caveolae. It was 
therefore hypothesised that loss of PIP2 turnover was due to 
its own delocalisation and not that of the EGFR or PLC. 
  A separate study by Han et al. [72] placed another down-
stream effector of EGFR signalling, phospholipase D1 
(PLD1) in the caveolin-rich membrane fraction of COS-7 
cells. Stimulation by EGF caused phosphorylation of PLD1 
in the caveolin-rich fraction, with kinetics similar to which 
protein kinase C appeared in this fraction. Palmitoylation 
of PLD1 was required for its location within the caveolin-
rich fraction, and for its activation via the EGFR, which re-
sulted in the local production of the secondary messenger 
PA. 
Evidence that Caveolae Inhibit EGFR Signalling 
  Several lines of evidence dispute the idea that caveolae 
are the locations of EGFR signalling, and suggest that caveo-
lae may in fact have a negative regulatory role. More pre-
cisely it appears that the scaffolding domain of caveolin-1 
stabilizes the EGFR kinase in an inactive conformation [83], 
and the same negative regulation also exists in the case of 
the ErbB2 tyrosine kinase activity [84, 85]. Couet et al. [83] 
demonstrated the co-fractionation of the EGFR, and its close 
relative ErbB2, with caveolin. They went on to show that the 
EGFR coimmunoprecipitated with caveolin-1, and that the 
scaffolding domain of caveolin-1 (residues 82-101) could 
bind to the EGFR in vitro. A caveolin-binding motif was 
identified in the cytoplasmic kinase domain of EGFR, and is 
conserved in most receptor tyrosine kinases. In addition, the 
caveolin-1 scaffolding domain dose-dependently inhibited 
 
Fig. (2). The EGFR signalling pathway in lipid rafts. See text for description of the pathway. The PLD shown here is PLD-2, which is 
activated directly by the EGFR. It must be also emphasised that at least three steps contribute to activation of Akt: (i) binding of 
PIP3/PI(3,4)P2 to its Pleckstrin Homology domain; (ii) phosphorylation on Thr308 by PDK1; and (iii) phosphorylation on Ser473. PLD: 
phospholipase D; PA: phosphatidic acid; PC: phosphatidylcholine; mTOR: mammalian target of rapamycin; EGFR: epidermal growth factor 
receptor; FKHR: Forkhead Box, subgroup O, transcription factors; CREB: cAMP response element binding protein; PDK1: 3-
phosphoinositide-dependent kinase-1; PI3K: phosphatidylinositol 3-kinase; PIP2: phosphatidylinositol-4,5-bisphosphate; PI(3,4)P2: phos-
phatidylinositol-3,4-bisphosphate; PIP3: phosphatidylinositol-3,4,5,-trisphosphate; S6K1: ribosomal protein S6 kinase 1. 18    The Open Biochemistry Journal, 2007, Volume 1  de Laurentiis et al. 
the kinase activity of the EGFR in vitro. The interaction was 
independent of EGFR activity and did not require tyrosine 
phosphorylation of caveolin-1. 
  Interestingly, it has been shown that overexpression of 
ganglioside GM3 causes increased interaction of the EGFR 
with caveolin-1 and hence inhibits EGFR signalling [40]. 
Furthermore, Engelman et al. [86] showed that overexpres-
sion of caveolin-1 in a fibroblast cell line inhibited signal 
transduction by the EGFR. Caveolin-1 expression also inhi-
bited the activity of Raf-1, MEK-1 and Erk2, and the 
scaffolding domains of caveolin-1 and caveolin-3, but not 
that of caveolin-2, could directly inhibit the activity of MEK-
1 and Erk2 in vitro. In addition, downregulation of caveolin-
1 causes hyperactivation of the same kinase cascade [87]. 
 Zhang  et al. [88] also provided evidence that caveolae 
inhibit EGF signalling. They observed that motile mammary 
adenocarcinoma cells failed to express normal levels of 
caveolin-1, in contrast to their non-motile counterparts. Ex-
pression of caveolin-1 in motile cells inhibited EGF-
dependent lamellipod extension and migration in the motile 
cell line. It was also shown to prevent activation of the 
p42/44 MAP kinase cascade, which is possibly one mecha-
nism by which it blocks migration. 
  Further evidence of an inhibitory role for caveolae came 
from a study on senescent cells by Park et al. [89]. Senescent 
cells show a decreased response to EGFR signalling, and the 
phosphorylation of Erk1/2 upon EGFR activation was de-
layed in senescent fibroblasts. Furthermore, they found that 
the levels of both caveolin-1 and caveolin-2 were signifi-
cantly increased in senescent cells compared with young 
cells, and that old fibroblasts contained over 10 times more 
caveolae. They also reported that all the major organs in old 
rats showed increased numbers of caveolae in their cells, and 
that the increase in caveolae numbers was accompanied by 
an increase in cellular cholesterol levels. In artificially aged 
cells, which did not overexpress caveolin, the response to 
EGF was not reduced, as it would be in normally aged cells. 
Moreover, overexpression of caveolin-1 in young cells inhi-
bited Erk1/2 activation upon EGF stimulation. This suggests 
that caveolin plays a role in the age-related decrease in 
EGFR signalling, though other factors might also be in-
volved. 
Evidence for the Involvement of Lipid Rafts in EGFR Sig-
nalling 
  Another line of evidence implicates lipid rafts, and not 
caveolae, in EGFR signalling. Firstly, Waugh et al. [90] 
showed that, although the EGFR was present in the low 
buoyant density, caveolin-rich fraction from A431 cells, it 
could not be co-immunoprecipitated with caveolin, and was 
soluble in Triton X-100, in contrast to caveolin, which was 
insoluble. Phosphorylated EGFR also did not co-immuno-
precipitate with caveolin-1, arguing against a caveolar loca-
tion for EGFR signalling. 
 Roepstorff  et al. [60] showed that depleting cholesterol 
from the membrane increased ligand binding to the EGFR. 
Depletion of cholesterol seemed to have this effect by in-
creasing the number of available receptors in the membrane, 
although the total number of receptors was not changed [91]. 
It was also demonstrated that oncogenic EGFRs reside in 
caveolae even after ligand binding, genereting altered signal-
ing pathways such as the enhanced tyrosine phosphorylation 
of the caveolar molecules, caveolin-1 and dynamin [81]. Li 
et al. [92] demostrated that the depletion of cholesterol also 
induces rafts disruption with a consequent Bcl-XL downregu-
lation and Akt inactivation. It is intriguing that EGF adminis-
tration after caveolae disruption could not restore Akt activa-
tion once rafts were disrupted, but cholesterol administration 
restored Akt activity also in absence of EGF [92, 93]. 
 Roepstorff  et al. [60] used immunofluorescence to study 
the relative locations of caveolin and the EGFR on the plas-
ma membrane, and did not find any significant co-
localisation. Finally, it was found that although caveolin-1 
was insoluble in Triton X-100, the EGFR was soluble in this 
detergent, but insoluble in another detergent, Brij 58, sup-
porting the idea that it is present in Brij 58-insoluble rafts. It 
is unknown whether these are a subset of rafts or whether 
this reflects a certain type of association of the EGFR with 
rafts [92]. The authors of this paper suggested that sequestra-
tion in rafts inhibits ligand-binding to the growth factor re-
ceptor, and that depletion of cholesterol allows release of the 
EGFR from rafts, thereby increasing its activation. 
 Ringerike  et al. [94] used immuno-electron microscopy 
to show that only 7% of EGFRs in A431 cells were localised 
in caveolae. In contrast to the results reported in [80], they 
did not find any difference in the distribution of EGFRs fol-
lowing stimulation with EGF. As in Roepstorff et al. [60], a 
co-localisation of the EGFR with markers of lipid rafts was 
found, and approximately 40% of receptors were present 
within rafts, which did not change following stimulation 
with EGF. Depletion of cholesterol increased dimerization of 
the EGFR, but, in contrast to [60], an increase in EGFR lev-
els at the plasma membrane was observed following choles-
terol depletion. Further support came from Ushio-Fukai et al. 
[95], who found that depletion of cholesterol enhanced EGF-
mediated autophosphorylation of the EGFR. 
  Matveev and Smart [96] showed that, although present in 
the caveolin-rich fraction, only 3% of EGFRs in Swiss 3T3 
cells co-immunoprecipitated with caveolin in unstimulated 
cells, with similar results obtained for cells exposed to EGF 
for ten minutes. However, the EGFR did co-immuno-
precipitate with CD55, a marker of lipid rafts, and was of a 
molecular weight consistent with tyrosine phosphorylation. 
Interestingly, in cells stimulated with EGF for 60 minutes, 
87-94% of EGFRs co-precipitated with caveolin. At this 
time, the EGFRs were no longer phosphorylated, which they 
had been after ten minutes’ treatment with EGF. This sug-
gests that signalling might actually occur in rafts, and that 
sequestration in caveolae following prolonged exposure to 
ligand may facilitate receptor desensitisation. This is in 
agreement with the idea that caveolae inhibit EGFR signal-
ling; however, it contradicts the results of Roepstorff et al. 
[60] and Ringerike et al. [94], which suggest that rafts also 
are inhibitory, and is also in direct contradiction to the re-
sults of Mineo et al. [80, 81]. 
  The results of Zhuang et al. [97] suggested an activatory 
role for lipid rafts in EGFR signalling. This study used the 
prostate cancer cell line LNCaP, which was shown to contain 
Triton X-100-insoluble fractions, but not caveolin-1. It was 
found that, in unstimulated cells, the EGFR was present in 
detergent-soluble, but not insoluble membranes. Following 
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detergent-insoluble fraction, but was not detected in the 
soluble fraction. In addition, treatment with filipin decreased 
the amount of phosphorylated EGFR in the insoluble fraction 
following EGF stimulation, but this was restored to normal 
following the addition of cholesterol. The presence of caveo-
lin also did not alter the levels of Akt activation before cho-
lesterol depletion, suggesting that caveolin-1 might not in-
hibit this pathway as it does MAPK. 
 Babuke  et al. [37] also recently demonstrated a role for 
reggie-1 in EGFR signaling. After EGFR activation, reggie-1 
colocalized with the receptor in the plasma membrane and 
the endosomes. It was also evident that its Tyr phosphoryla-
tion involved Src kinases [98]. A role for reggie-2 in raft-
mediated endocytosis has also previously been suggested 
[99]. These results open the interesting possibility that reggie 
can also play a role in the raft-mediated endocytosis and sig-
naling of the EGFR [100] which also involves Src kinases 
[101]. 
  In summary, most evidence indicates an inhibitory role 
for caveolae in EGFR signalling, which might contribute to 
the desensitisation of receptors [96]. Furthermore, as Park et 
al. [89] demonstrated that older cells, which have a reduced 
response to EGF, have elevated numbers of caveolae, it is 
likely that one way in which cells can control the level of 
signalling by the EGFR is by regulating their number of 
caveolae. However, it is possible that caveolae only inhibit 
certain downstream pathways, such as MAPK, and not oth-
ers, such as PI3K/Akt. There is a certain amount of dis-
agreement in the data concerning whether lipid rafts play an 
inhibitory or activatory role in EGFR signalling, in that some 
researchers reported an increased level of signalling follow-
ing cholesterol depletion, while others have located activated 
EGFRs in lipid raft fractions. Given that the cells used by 
Roepstorff et al. [60] and Ringerike et al. [94] also contained 
caveolae, however, and the fact that phosphorylated EGFRs 
were clearly localised to rafts by Zhuang et al. [97] and Mat-
veev and Smart [96], it is likely that lipid rafts could play an 
activatory role in EGFR signalling. The bulk of the evidence 
suggests that the EGFR is constitutively present in rafts, but 
that its association with rafts is probably strengthened fol-
lowing activation, causing it to become insoluble in Triton 
X-100. It could then initiate signalling pathways in these 
domains, which contain a number of molecules downstream 
from the receptor. 
Association of Downstream Signalling Pathways with Rafts 
  Assuming that EGF signalling is localised to rafts, it is 
necessary to note that not all the downstream molecules may 
act in these domains. For example, there is evidence to sug-
gest that activated Ras might act outside of rafts. There are 
three isoforms of Ras: N-Ras, H-Ras and K-Ras, of which K-
Ras is most efficient at activating Raf, while H-Ras effi-
ciently activates PI3K [102]. Fukano et al. [103] used im-
munogold labelling to show that some H-Ras, but not K-Ras, 
was localised to caveolae, and that non-caveolar H-Ras co-
localised with a marker of lipid rafts, while K-Ras did not. 
However, activated H-Ras (G12V) was almost completely 
excluded from the caveolae/raft fraction. More recently, 
Prior et al. [104] reported that H-Ras exists in a dynamic 
equilibrium between lipid rafts and non-raft membrane. 
However, constitutively active H-Ras (G12V) was not loca-
lised to lipid rafts, but to cholesterol-independent microdo-
mains. They also examined the distribution of K-Ras, and 
found that it was localised to cholesterol-independent micro-
domains. Together, these results indicate that K-Ras and H-
Ras occupy different microdomains, and that activated Ras is 
not associated with rafts. 
  Given that activated Ras is excluded from rafts, pre-
sumably it activates Raf outside of rafts, and it seems strange 
that Mineo et al. [80] found phosphorylated Raf-1 in rafts, 
suggesting that it returns to these domains upon activation. 
However, Chen and Resh [105] created several Raf-1 cons-
tructs that localised to rafts to different extents, and the ex-
tent of localisation to rafts did not affect the extent of Erk 
activation, Erk being excluded from rafts. The cholesterol 
depletion data gave varying results: Peiro et al. [106] found 
that cholesterol depletion did not affect MAPK activation by 
the EGFR, while Chen and Resh [105] found that MAPK 
activation was increased, but that this occurred via  PI3K. 
They suggest that it is due to factors other than raft disrup-
tion. Furuchi and Anderson [107] also detected increased 
EGF-stimulated Erk activation following cholesterol deple-
tion. These results are complicated by the presence of caveo-
lae, and the recent discorvery of a cholesterol-regulated Erk 
phosphatase [108]. Therefore the evidence suggests that, 
although H-Ras is probably activated in rafts initially (given 
that the EGFR, Grb2, Sos and Shc have been found in rafts 
[57, 80]), activated Ras moves out of rafts to activate Raf, 
and a raft location for Raf is not strictly required for activa-
tion of Erk. However, as mentioned in below sections, stud-
ies of other systems have shown that cholesterol depletion 
can inhibit the MAPK pathway, suggesting that this may 
vary depending on the receptor involved. 
  Alternative pathways are related to Ras activation and 
can act in balance with the EGFR, one of the most important 
already described is the presence in lipid rafts of the Spred-1 
protein. This protein, recruited to the lipid raft/caveolae, effi-
ciently interacts with Ras and also Raf-1 by interacting via 
caveolin-1, resulting in a strong inhibition of the Ras/ERK 
pathway [109]. 
  As mentioned above, the activation of PLC by EGF sig-
nalling is not affected by cholesterol depletion, suggesting 
that a raft location is also not required for the activation of 
this pathway [82]. However, this study also showed that PIP2 
turnover was dependent on rafts. There is also evidence that 
PLD is activated in rafts: Han et al. [72] localised activated 
PLD in caveolae/raft fractions following stimulation with 
EGF. In addition, there is evidence that the PI3K/Akt path-
way is localised to rafts, as cholesterol depletion prevented 
EGF-induced phosphorylation of Akt [92]. Furthermore, 
PIP2, a substrate of PI3K, has been found in rafts [110], as 
has the Akt Ser473 kinase [78]. Hill et al. [78] therefore hy-
pothesise that a constitutively active Ser473 kinase is present 
in rafts, and the activation of PI3K (e.g., by the EGFR) and 
subsequent generation of PIP3 from PIP2 results in the re-
cruitment of PDK1 and Akt to rafts. 
  In summary, most of the published evidence suggests a 
raft localisation for PLD and the PI3K pathway. In particu-
lar, as cholesterol depletion prevents Akt phosphorylation 
[92], a raft localization may be required for adequate func-
tioning of this pathway. In contrast, Ras acts outside of rafts, 
and while activated Raf and PLC have been found in rafts, 
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Therefore, different pathways downstream from the EGFR 
might be differentially dependent on lipid rafts for their acti-
vation. 
2) Platelet-derived Growth Factor Receptor (PDGFR) 
Structure and Function of the PDGFR 
  There are two types of PDGFR: the -receptor 
(PDGFR) and the -receptor (PDGFR), which bind dif-
ferent PDGF types and have distinct but overlapping cellular 
distributions [111]. The two receptors have a similar struc-
ture, possessing five immunoglobulin-like domains extracel-
lularly, and in the intracellular region a juxtamembrane do-
main, tyrosine kinase domain and C-terminal domain. This is 
reminiscent of the EGFR; however, a distinguishing feature 
of the PDGFR is that its kinase domain is split in two by a 
non-kinase 100 amino acid insert [111, 112]. Upon binding 
of ligand, the receptor dimerises, and can form either homo- 
or heterodimers, depending on the isoform of PDGF [112]. 
As for the EGFR, activation results in autophosphorylation 
of the receptor, increasing its kinase activity and providing 
docking sites for proteins with SH2 domains. Downstream 
molecules activated by the PDGFR include PI3K, PLC, 
several members of the STAT family and the non-receptor 
tyrosine kinase Src. It can also activate the Ras/MAPK 
pathway via Grb2 and SOS [111]. Activation of the PDGFR 
provokes several responses: early responses include intracel-
lular Ca
2+ flux and the reorganisation of the cytoskeleton, 
resulting in the formation of plasma membrane processes. 
Later effects include cell migration, proliferation and differ-
entiation [112]. 
Involvement of Lipid Rafts and Caveolae in Signalling by 
the PDGFR 
  Again there are a number of conflicting results concern-
ing the role of lipid rafts and caveolae in PDGFR signalling. 
Some studies suggest that caveolae are the sites of signal-
ling; some suggest that caveolae are inhibitory and that sig-
nalling occurs in rafts. 
 Liu  et al. [113] localised the PDGFR to the low buoyant 
density, caveolin-rich fraction of human fibroblasts, indicat-
ing that it was present in either caveolae or rafts. They then 
used immunocytochemistry to demonstrate that the PDGFR 
was found in distinct patches on the cell surface, and that it 
co-localised with caveolin in caveolae-like structures. Fol-
lowing stimulation with PDGF, phosphorylated PDGFR 
was found in the caveolin-rich fraction, as were increased 
amounts of the tyrosine phosphatase Syp, Shc, and MAPK. 
However, it is important to note that this fraction will also 
have contained lipid rafts. 
 Liu  et al. [114] first showed by immunoblotting that the 
PDGFR, Ras, Raf-1, MEK-1 and Erk2 were all present in 
caveolae/raft fractions from unstimulated human fibroblasts. 
The localization of Erk2 and the PDGFR in caveolae was 
confirmed using immunocytochemistry. Stimulation with 
PDGF resulted in accumulation of a number of phosphory-
lated proteins, including activated MAPK, in the caveo-
lae/raft fraction. Immunogold labelling seemed to confirm 
the presence of tyrosine-phosphorylated proteins in caveolar 
structures following but not prior to PDGF treatment. Liu  et 
al. [115] used a technique designed to separate caveolae 
from lipid rafts, and found the PDGFR to be associated 
with these domains, along with molecules known to act 
downstream of the receptor, such as PLC, PI3K and non-
receptor tyrosine kinases. In addition, they used confocal 
immunofluorescence microscopy to show that PDGF treat-
ment caused tyrosine phosphorylation of proteins in caveo-
lae, both in cell culture and in intact rat lungs. Disruption of 
caveolae by cholesterol depletion prevented PDGF-induced 
tyrosine phosphorylation; the PDGF receptor itself was 
phosphorylated, but less so than in the control. On the other 
hand, tyrosine phosphorylation by vanadate was not reduced 
by cholesterol depletion. Again it must be noted that choles-
terol depletion also affects rafts, and can often give unreli-
able and conflicting results. 
  The results related above suggest a caveolar location for 
PDGF and at least some PDGF-induced tyrosine phosphory-
lation. However, this does not agree with the observation of 
Couet et al. [83], since the PDGFR contains a motif associ-
ated with binding to the scaffolding domain of caveolin, an 
interaction which is usually inhibitory. Furthermore, Yama-
moto  et al. [116] showed that both the PDGFR and 
PDGFR, which were present in the caveolae/raft fraction, 
could be immunoprecipitated with caveolin-1. Moreover, the 
phosphorylation of PDGFRs was inhibited in a dose-
dependent manner by the scaffolding domains of both caveo-
lin-1 and caveolin-3, but not caveolin-2. 
  Work by Matveev and Smart [96] also suggested an in-
hibitory role for caveolae, and localised PDGF signalling to 
rafts. They showed that, although the PDGFR was located in 
the caveolin-rich, caveolae/raft fraction, it coimmunoprecipi-
tated with CD55, a marker of non-caveolar rafts, and only 
3% co-immunoprecipitated with caveolin. Following treat-
ment with PDGF, the PDGFR that co-immunoprecipitated 
with CD55 was of a molecular weight consistent with tyro-
sine phosphorylation; little PDGFR precipitated with caveo-
lin. However, most of the PDGFR co-immunoprecipitated 
with caveolin after exposure to PDGF. This is similar to the 
results obtained for the EGFR in the same paper. Indeed, 
antibodies to the PDGFR precipitated membranes containing 
the EGFR and vice versa, suggesting that the two receptors 
are present in the same microdomains. This is supported by 
the fact that Matveev and Smart [96] showed that pre-
treatment of Swiss 3T3 cells with either EGF or PDGF for 
60 minutes caused sequestration of the receptor for the other 
ligand, preventing ligand binding and activation. Filipin and 
the cholesterol-depleting agent methyl--cyclodextrin al-
lowed re-exposure of the same receptors. Pre-treatment with 
either of these substances also prevented sequestration of 
either receptor. Sequestration was also prevented in cells 
lacking caveolin-1, supporting a role for caveolae. This indi-
cates that cross-talk between the PDGFR and EGFR occurs, 
supporting the hypothesis that they are present in the same 
microdomains, and implicates caveolae as sites of sequestra-
tion. 
  The results just reported are very difficult to reconcile. 
The results of Liu et al. [113-115] suggest that PDGF signal-
ling occurs in caveolae; however, the more recent study by 
Matveev and Smart [96] suggests that the PDGFR is nor-
mally located in lipid rafts, and re-localises to caveolae after 
prolonged exposure to ligand. In support of a role for lipid 
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the EGFR, suggesting that they are present in the same mic-
rodomains. As discussed above, most evidence suggests that 
the EGFR is associated with rafts. 
  It is possible that some PDGFR is present in lipid rafts 
and some in caveolae. Although Liu et al. [113, 114] demons-
trated that the PDGFR was present in caveolae, their immu-
nocytochemistry/immunogold labelling do show that it is 
also present outside of caveolae; as it was detected mainly in 
caveolae/raft fractions, it is therefore likely to be also present 
in rafts. In addition, the tyrosine-phosphorylated proteins 
detected by Liu et al. [113, 115] were present in the caveo-
lae/raft fraction and could have been associated with rafts. 
  In summary, it is not possible to say with certainty what 
the role of lipid rafts and caveolae is in signalling by the 
PDGFR, although the location of phosphorylated proteins in 
the caveola/raft fraction, including MAPK [114] suggests 
that at least one of these domains is involved in signalling. 
This is supported by a paper by Mitsuda et al. [117], who 
showed that overexpression of the ganglioside GM1 resulted 
in the re-location of the PDGFR to non-raft/caveolar mem-
brane and hence an inhibition of PDGFR signalling. 
3) c-Kit- the Stem Cell Factor Receptor 
  c-Kit is a type III receptor protein-tyrosine kinase, in a 
class which also includes the PDGFR, and the CSF-1R. Its 
extracellular N-terminal domain binds to stem cell factor 
(SCF) and then induces the dimerization of the receptor re-
sulting in activation of the cytoplasmic catalytic activity. 
This cytoplasmic domain is needed, together with adaptor 
proteins such as Grb2 and Grb7, to activate several down-
stream pathways. One of the most important downstream 
mediators of c-Kit is PI3K, which then activates Akt, a pro-
tein-serine/threonine kinase, promoting cell survival [118, 
119]. Other downstream effectors of c-Kit include the 
Ras/mitogen-activated protein kinases and activators of tran-
scription (Jak/STAT) pathways [120]. 
  Lipid raft clustering was shown after SCF stimulation of 
hemoatopoietic stem cells (HSCs) and correlated with acti-
vation of the Akt-FOXO signalling pathway [121]. Inhibition 
of lipid raft clustering attenuated SCF signalling and pre-
vented hibernating HSCs from re-entering the cell cycle 
[121]. Jahn et al. [122] showed the translocation of c-Kit to 
lipid rafts after activation of the receptor by ligand binding. 
The receptor was then co-localized with signalling mediators 
such as PDK1 and Akt that transduce the survival signal of 
SCF/c-Kit [122]. Arcaro et al. [110] presented evidence that 
SCF stimulation induces Src kinase activation in the deter-
gent-insoluble fraction of small cell lung cancer (SCLC) cell 
lines. Src kinase activity was required for optimal Akt acti-
vation, which was supported by the fact that Src and PI3K 
associated in the lipid rafts fraction of SCLC cells [110]. 
They also demonstrated that on the other hand, the activation 
of the Erk pathway after SCF stimulation is independent 
from the integrity of lipid rafts [110, 123]. 
4) Insulin-like Growth Factor-1 Receptor (IGF-1R) 
  The IGF-1R binds to and mediates the cellular effects of 
IGF-1, and also binds with lower affinity to IGF-2 [124]. 
Like other tyrosine kinase receptors, it contains extracellular 
ligand-binding and cysteine-rich domains, a transmembrane 
domain and an intracellular kinase domain. However, it is 
unusual in existing as a dimer on the cell surface prior to 
stimulation, and so depends on domain rearrangements 
rather than dimerisation in order to initiate signalling [124]. 
Downstream pathways activated by the IGF-1R include the 
p42/44 MAPK pathway and the PI3K/Akt pathway. The 
IGF-1R is expressed in a wide range of tissues, and its acti-
vation can lead to proliferation, differentation and the pre-
vention of apoptosis [124]. 
 Ravid  et al. [125] demonstrated that constitutive over-
expression of caveolin-1 in MCF-7 breast cancer cells inhi-
bits anoikis by attenuating p53 and p21 activation. From this 
observation they went further, demonstrating that Akt sub-
strate (pp340) phosphorylation is constitutively present, acti-
vating the protein and the signalling through it. The signal 
through the ERK1/2 pathway was also increased [126]. This 
study together with others demonstrates that IGF-1R stimu-
lation induces anchorage-independent survival of the cells, 
through caveolin-1 and Akt, leading to a highly motile phe-
notype of MCF-7 cells [125, 126]. 
 Podar  et al. [127] found that depletion of cellular choles-
terol prevented recruitment of PI3K to caveolae/rafts by 
IGF-1, inhibited IGF-1-induced IRS1 (insulin receptor subs-
trate 1 – an adapter protein recruited by the IGF-1 receptor) 
phosphorylation, and blocked IGF-1-stimulated PI3K and 
Akt activation, but not Erk phosphorylation. However, cho-
lesterol depletion data are complicated by a number of fac-
tors, including the existence of a cholesterol-regulated Erk 
phosphatase [108], and so are not too reliable. Nevertheless, 
the fact that Erk was not found in the caveolae/raft fraction 
indicates that it does not signal in these domains, in support 
of results reported above. 
 Maggi  et al. [128] overexpressed human IGF-1R in 
mouse fibroblasts, and localised the IGF-1R to the caveolin-
rich fraction upon ultracentrifugation in a sucrose gradient. 
They also showed that IGF-1 stimulation resulted in phos-
phorylation of caveolin-1 on tyrosine 14. Furthermore, IGF-
1 seemed to cause translocation of caveolin-1 from the frac-
tion in which it is normally present (fraction 7) to the lighter 
fractions 5 and 6, which are thought to contain lipid rafts. 
 Huo  et al. [129, 130] also found that IGF-1 was present 
in the caveolae/raft fraction of 3T3 preadipocytes, and 
showed by double immunofluorescence staining that the 
IGF-1R co-localised with caveolin-1 in these cells. Fur-
thermore, the IGF-1R was shown to co-immunoprecipitate 
and to interact with caveolin-1, and caveolin associated with 
the activated IGF-1R just as it did with the quiescent recep-
tor. This seems to suggest that caveolin-1 does not, in this 
case, prevent receptor activation. Because the IGF-1R was 
present not only in fractions containing caveolin but also in 
some lighter fractions, Huo et al. [129, 130] suggested that it 
was also present in non-caveolar lipid rafts. It was shown 
that disrupting lipid rafts and caveolae by cholesterol deple-
tion inhibited IGF-1-induced differentiation of preadipocytes 
into adipocytes, as well as IGF-1-induced clonal expansion. 
This was not due to inhibition of receptor activation, but to 
an inhibition of the downstream molecules Erk1 and Erk2. 
These results are however in contrast with those of Matthews 
et al. [131], who concluded that rafts were not involved in 
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tial components in the transduction of the biological actions 
of IGF-1. 
  The results of Huo et al. [129], who found that lipid 
rafts/caveolae are required for IGF-1-induced adipocyte dif-
ferentiation, are interesting in light of the results of Razani et 
al. [132]. These researchers fed caveolin-1 knockout mice on 
a high fat diet, and found that these mice were resistant to 
diet-induced obesity, and showed reduced adiposity as they 
grew older. As Huo et al. [129] point out, this suggests that 
these mice have abnormal adipocyte differentiation in adult-
hood, and supports a role for caveolae in adipocyte differen-
tiation, possibly via the IGF-1R. 
  In summary, the data so far suggests that the IGF-1R is 
associated possibly with both lipid rafts and caveolae, and 
that one or both of these domains are involved at least in 
downstream signalling from the receptor. Further work is 
clearly required to determine whether rafts and caveolae 
have a distinct role in IGF-1R signalling, and for example to 
determine the significance of the observed translocation of 
caveolin-1 into supposed lipid raft fractions following IGF-1 
stimulation [128]. 
5) Nerve Growth Factor (NGF) Receptors (TrkA and 
p75
NTR) 
  NGF is a member of the neurotrophin family of growth 
factors, and can activate two receptors: TrkA and the p75 
neurotrophin receptor (p75
NTR). TrkA is a tyrosine kinase 
receptor, through which NGF signals cell survival, and 
p75
NTR is a member of the tumour necrosis factor receptor 
family, which induces cell apoptosis [133]. TrkA has a simi-
lar structure and function to the tyrosine kinase receptors 
discussed above; it can associate with the adapter protein 
Shc, PI3K and PLC, and is capable of activating the 
Ras/MAPK pathway [134]. The activation of p75
NTR may 
result in the generation of ceramide (via sphingomyelin hy-
drolysis), activation of the JNK (Jun N-terminal kinase) 
pathway and activation of the transcription factor NF-B 
[135]. 
 Bilberback  et al. [136] demonstrated that p75
NTR was 
present in the caveolae/raft fraction from p75-NIH 3T3 cells, 
and that it co-immunoprecipitated with caveolin. They also 
localised p75
NTR-induced sphingomyelin hydrolysis to this 
fraction. Wu et al. [56] localised TrkA to low buoyant den-
sity fractions lacking caveolin, suggesting that it is present in 
rafts, and Huang et al. [137] demonstrated that 40% of TrkA 
and 60% of p75
NTR in 3T3-TrkA-p75 cells was present in the 
caveolae/raft fraction. p75
NTR co-immunoprecipitated with 
caveolin either with or without NGF treatment; however, the 
co-immunoprecipitation of TrkA with caveolin could not be 
demonstrated. Possibly the interaction was of low affinity, as 
the results of Bilberback et al. [136] (see below) suggest that 
TrkA can interact with caveolin. Cholesterol depletion using 
filipin altered the distribution of TrkA and inhibited its 
phosphorylation by NGF. 
 Huang  et al. [137] also used PC12 cells, and could not 
detect caveolin-1 in these cells; however, in the paper 
dicussed below, Peiro et al. [106] did detect caveolin and 
caveolae in PC12 cells. This issue is therefore controversial. 
Nevertheless, Huang et al. [137] showed that TrkA and 
p75
NTR were present in low buoyant density (caveolae/raft) 
fractions in these cells in similar proportions to those in 3T3-
TrkA-p75
NTR cells. Following treatment with NGF, NGF-
bound TrkA and p75
NTR were detected both in the low buoy-
ant density fractions and other membrane fractions. How-
ever, more NGF-bound receptor seemed to be present in the 
low buoyant density fractions, and these fractions seemed to 
be enriched in higher affinity receptors, especially with re-
gard to TrkA. Furthermore, activated TrkA was enriched in 
these fractions compared to other fractions following NGF 
stimulation. Huang et al. [137] then examined downstream 
molecules of TrkA, and found that, although not present 
solely in the caveolae/raft fraction, the adapter molecule Shc 
only co-immunoprecipitated with activated TrkA in this frac-
tion. A similar result was found for PLC. This suggests that 
NGF signalling via these molecules at least is localised to 
caveolae or rafts. 
 Peiro  et al. [106] used double immunofluorescence mic-
roscopy and immunogold techniques to show that a fraction 
of TrkA co-localised with caveolin and was present in the 
caveolae of PC12 cells. Depletion of cholesterol resulted in 
an increased basal level of MAPK activity, but inhibited the 
activation of MAPK by TrkA, although not affecting NGF-
induced phosphorylation of TrkA. This also suggests an in-
volvement of caveolae and/or lipid rafts in TrkA signalling. 
In addition, it suggests that the requirement for lipid rafts for 
MAPK activation may depend on the system studied and 
receptor involved, as in the same study it was found that 
EGF-stimulated MAPK activation was not affected by cho-
lesterol depletion. As emphasised above, however, other 
factors may be involved. 
  On the other hand, the results of Bilberback et al. [136] 
suggest an inhibitory role for caveolae. They showed that 
transfection of PC12 cells (which they found to express only 
very low endogenous levels of caveolin-1) with caveolin-1 
suppressed NGF-induced differentiation, which usually re-
sults in the development of neurites. In addition, although 
TrkA was autophosphorylated both in these cells and normal 
PC12 cells after 15 minutes’ treatment with NGF, after this 
time TrkA autophosphorylation was rapidly abrogated in 
cells that had been transfected with caveolin. They also 
demonstrated that TrkA interacted with caveolin-1, as did 
p75
NTR, and an in vitro kinase assay indicated that caveolin-1 
inhibited NGF-induced TrkA autophosphorylation. The 
authors conclude that caveolae play a negative regulatory 
role in TrkA signal transduction. 
  More recently, additional studies about Trk receptor fam-
ily (TrkA, TrkB and TrkC) were published, especially re-
garding the neuronal signaling cascade where these receptors 
are essential [56, 138]. Limpert et al. [139] demonstrated 
that following NGF stimulation, TrkA is concentrated 
whithin the lipid raft fraction of the plasma membrane. This 
is possibly due to the adapter function of CAP, which links 
TrkA-containing complexes to flottilin. It was also recently 
demonstrated that there is an interaction of TrkA and TrkB 
with Src family kinases, such as Fyn and Src [140, 141]. 
  The fact that Bilberback et al. [136] found that caveolin 
inhibits TrkA signalling suggests that rafts might be the 
more likely location of signalling, similar to the situation 
with the EGFR. Less information is available for p75
NTR, but 
p75
NTR-induced sphingomyelin hydrolysis at least has been 
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gest anyway, that TrkA, and possibly p75
NTR, are present in 
both rafts and caveolae. They also suggest that activation of 
Shc, PLC and MAPK by TrkA occurs in either lipid rafts of 
caveolae. 
6) Fibroblast Growth Factor Receptor (FGFR) 
  There are now four known FGFRs, designated FGFR1-4, 
all of which are tyrosine kinase receptors. FGFR activation 
can lead to activation of PLC, Src kinases and FGF receptor 
substrate 2 (FRS2). FRS2 in turn recruits Grb2, leading to 
the activation of the Ras/MAPK pathway, and can also acti-
vate protein kinase C [142]. FGF signalling has a number of 
effects, including the promotion of angiogenesis, wound 
healing and limb development. Unfortunately, only two stud-
ies have been performed concerning the role of lipid rafts 
and caveolae, as we will summarise below. 
 Davy  et al. [143] showed that FGF-2 was able to induce 
the tyrosine phosphorylation of proteins in the caveola/raft 
fraction of human neuroblastoma (LAN-1) cells. Some of 
this phosphorylation required Src kinases, of which Lyn and 
Fyn were found in the caveolae/raft fraction, and were phos-
phorylated following FGF-2 application. In addition, a 
downstream substrate of Src kinases, annexin II, was re-
cruited to the raft fraction upon FGF-2 treatment. The 
authors noted that FGFR-2 was present in these cells, but 
that it was soluble in Triton X-100; however, it does not nec-
essarily follow that FGFR-2 was not present in 
rafts/caveolae. It has been shown, for example for the EGFR 
[60], that proteins associated with rafts may be differentially 
soluble in different detergents. 
  Ridyard and Robbins [138] showed that FGF receptor 
substrate 2 (FRS2) was present in caveolae/rafts from LAN-
1 cells. FRS2 became serine-threonine phosphorylated fol-
lowing FGF-2 stimulation, and this required the activation of 
Src kinases, PKC, and MEK-1/2, suggesting an involvement 
of the MAPK cascade. FRS2 was also tyrosine-phosphory-
lated following FGF-2 treatment. The authors also observed 
that stimulation with FGF-2 resulted in the recruitment of 
Grb2, which is downstream of FRS2, to the raft fraction. 
Enhancing the tyrosine phosphorylation of FRS2 increased 
the recruitment of Grb2. The fact that FRS2 is myristoylated 
[144] may contribute to its localisation to rafts. 
  Both of the above studies suggest that membrane micro-
domains are involved in FGF signalling and activation of 
Grb2 and FRS2. 
CONCLUSIONS 
  Unfortunately, for many of the growth factor receptors 
discussed, little information is available concerning the role 
of lipid rafts and caveolae in signalling, and, in addition, 
much of the data exist is contradictory. This is due in part to 
the use of methods which do not completely isolate lipid 
rafts and caveolae, and the use of methods such as choles-
terol depletion, which can give unreliable results. Neverthe-
less, evidence does exist for the involvement of either lipid 
rafts or caveolae in some aspect of signalling for all the re-
ceptors discussed. For caveolae this role seems often, though 
possibly not always, to be an inhibitory one, due to the in-
hibitory interactions of caveolae with various proteins, in-
cluding the EGFR, TrkA, and components of the MAPK 
pathway. On the other hand, caveolae may not be capable of 
inhibiting some other downstream pathways, such as 
PI3K/Akt. 
  Many studies suggest that membrane microdomains can 
also act as ‘signalling platforms’ for growth factor receptors. 
For example, activated growth factor receptors and down-
stream molecules have been located in caveolae/raft frac-
tions, and in some cases cholesterol depletion has been 
shown to inhibit growth factor signalling (e.g., see PDGF, 
IGF-1, NGF). The fact that caveolin-1 inhibits several 
growth factor receptors and their downstream molecules 
makes it more likely that rafts in general are the sites of sig-
nal initiation. However, it is possible that caveolae may have 
a role in downstream signalling from the PDGFR, and 
caveolin has not been shown to inhibit the IGF-1R. An 
added complication is the fact that only some downstream 
molecules require rafts to signal: these include the PI3K/Akt 
and PLD pathways. With regard to the MAPK pathway, the 
situation seems to be more complicated: activated Ras seems 
to move out of rafts, but there is disagreement as to whether 
Erk activation requires rafts. Possibly this depends on the 
system studied, but the results are complicated by the many 
effects of cholesterol depletion. 
  Clearly much further work is required to determine the 
exact role of rafts and caveolae in signalling from the growth 
factor receptors mentioned. The EGFR is the only receptor 
for which quite a large amount of information is available, 
and the bulk of the evidence suggests that caveolae inhibit 
signalling, while lipid rafts are likely to act as signalling 
platforms at least for signalling via PLD1 and PI3K/Akt. 
INVOLVEMENT OF LIPID RAFTS AND CAVEOLAE 
IN MALIGNANT TRANSFORMATION 
  The fact that lipid rafts and caveolae have been impli-
cated in signalling by growth factor receptors, which are 
involved in the regulation of proliferation, differentiation, 
apoptosis and cell migration, suggests the possibility that the 
alteration of these domains could be involved in malignant 
transformation. So far, most of the evidence for this theory 
relates to caveolae, and, as we will describe, caveolin-1 has 
been identified as a possible tumour suppressor gene. Firstly, 
however, we will discuss a possible role for lipid rafts in 
cancer. 
1) Lipid Rafts 
  The central role that lipid rafts play in cancer develop-
ment and metastasis has become evident only in the recent 
few years. Lipid rafts are areas where many growth factor 
receptors have been shown to localize, and thus it was obvi-
ous to think of these domains as a possible location where 
cell signalling events can be altered. Some reports such as 
Liu et al. [145] have provided clear evidence that disruption 
of rafts inhibits EGF-induced chemotaxis of human breast 
cancer cells. Further investigations also revealed impared 
directional migration of cells, EGF-induced cell adhesion, 
actin polymerization and also translocation of some recep-
tors. 
  Upregulation of the PI3K pathway in cancer often occurs 
due to a defect in the PTEN (phosphatase and tensin homo-
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which is mutated in numerous cancers [146]. PTEN dephos-
phorylates phosphatidylinositol phosphates (e.g., PIP3, 
PI(3,4)P2), and when this activity is lost it can lead to consti-
tutive activation of Akt, and increased cancer cell survival 
and proliferation. Moreover, the PIK3CA gene, encoding the 
catalytic p110 isoform of PI3K is mutated in a variety of 
human cancers [147, 148]. These mutations constitutively 
activate the catalytic activity of PI3K and are oncogenic 
[149-151]. Consistent with this, Zhuang et al. [97] reported 
that an inhibitor of PI3K induced apoptosis of LNCaP cells, 
while the effect of this drug was reversed by treatment with 
EGF. They localised the activated EGFR to rafts, and treat-
ment with filipin induced apoptosis to a similar extent as the 
PI3K inhibitor, and under these conditions EGF pre-
treatment could not prevent apoptosis. It was shown that 
filipin prevented constitutive and EGF-stimulated phos-
phorylation of Akt1, explaining its ability to induce apopto-
sis and prevent EGF-mediated survival. The authors interpret 
these results to mean that Akt signalling in these cells is still 
dependent on upstream signalling from the EGFR, and that 
EGFR signalling through Akt is dependent upon cholesterol-
rich lipid rafts. Transfecting cells with caveolin-1 did not 
change the effects of cholesterol depletion on EGFR/Akt 
signalling, suggesting that caveolae are not involved, and 
furthermore that lipid rafts have a similar effect in cells that 
do possess caveolae. 
  The results of Zhuang et al. [97] are interesting in the 
light of the fact that a link has been found between high fat 
intake and risk of prostate cancer [152-154], and Zhuang et 
al. [97] suggest that this might be related to high cholesterol 
levels. While depleting cholesterol disrupts rafts and de-
creases EGFR signalling, increasing cholesterol levels in-
creases the size of rafts [155] and possibly raft number. 
  Other receptors that are known to accumulate in lipid 
rafts are involved in the process of malignant transformation. 
Recently several authors have also focalized on the IGF-1R 
[156-158]. In the case of this receptor, most of the the evi-
dence seems to go into the direction of alterations in the 
PI3K/Akt pathway. Constitutively active TrkA mutants can 
also cause cellular transformation (e.g., in colon carcinoma 
or acute myeloid leukaemia) [159], and the PDGFR has been 
observed to be up-regulated or mutated in cancer [111]. 
Rafts also contain a number of other proteins that can cause 
cancer if mutated or misregulated, including PI3K, Ras, and 
Src. While it has been shown that constitutively active H-Ras 
is excluded from rafts [160], rafts could act to stabilise sig-
nalling from other oncogenic proteins like those just men-
tioned. Furthermore, if cholesterol levels were increased in 
cells transformed by these proteins, this could stimulate their 
signalling still further, exacerbating the problem. The recent 
finding that lipid rafts are the place where all these altered 
growth factor receptors initiate their signals, suggests that 
lipid rafts could be the target for new drug development. 
 Therefore  Zhuang  et al. [97] suggest that cholesterol de-
pletion could be a useful treatment for prostate cancer, and 
refer to a study by Gordon and Schaffner [161], who found 
that sterol-binding agents such as filipin reduced prostate 
gland hyperplasia in dogs with no toxicity. In support of the 
use of cholesterol depletion for cancer treatment are the re-
sults of Podar et al. [127]. Cholesterol depletion inhibited 
IGF-1-induced activation of PI3K and Akt in multiple mye-
loma cells, and induced G1 growth arrest. Given that muta-
tion in PTEN and PIKCA are commonly observed in human 
cancer [146, 147], the role of lipid rafts in activation of the 
PI3K/Akt pathway may be important in numerous malignan-
cies. However, there is still the possibility of cholesterol de-
pletion agents causing toxicity in humans, and in vivo studies 
of tumours are required to confirm the work of Zhuang et al. 
[97] regarding the link between high cholesterol, elevated 
signalling through the EGFR, and prostate cancer inci-
dence/progression. Intriguingly, caveolin-1 is often up-
regulated in prostate cancer cells [162], and its expression is 
known to be increased by high levels of cholesterol [22]. 
High cholesterol could therefore be the reason for this. How-
ever, as explained below, in other cell types caveolin-1 can 
act as a tumour suppressor, and cholesterol depletion has 
been shown to decrease caveolin-1 levels [23], so this treat-
ment might have deleterious effects in these types of cancer 
and would have to be used specifically. 
  Several already known anti-cancer agents have recently 
been found to inhibit tumor cells proliferation, or spreading 
through the disruption of lipid rafts components [163]. For 
instance, Huang et al. [163] have recently discoverd that 
Emodi, the major active component of Rheum palmotum L., 
with known anti-cancer activities, is able to induce a signifi-
cant decrease in cholesterol and sphingolipids in the raft 
fraction. Data from their study proved that Emodin, through 
the impairement of lipid raft-associated integrin signaling 
pathways inhibits adhesion and spreading of tumor cells. 
Similar results were found using different tumor types [164, 
165] and other drugs [166-168]. 
2) Caveolae 
  The fact that caveolin-1 is capable of suppressing the 
activity of many components of growth factor signalling 
pathways (e.g., the EGFR and components of the p42/44 
MAPK pathway [86, 88]), makes it an attractive candidate 
tumour suppressor gene, and several lines of evidence sup-
port this proposal. 
Caveolin-1 is Down-Regulated in Tumours and Tumour 
Cell Lines 
  Caveolin-1 has been observed to be down-regulated in a 
number of tumours and tumour cell lines. Firstly, Koleske et 
al. [169] showed that caveolin-1 mRNA was down-regulated 
in NIH 3T3 fibroblasts that had been transformed by a num-
ber of different oncogenes including v-Abl  and H-Ras
 
(G12V). Transformation of cells by v-Abl occurs at least 
partly via the Ras/MAPK pathway [170]. The transformed 
cells were examined under the electron microscope and ob-
served to contain few if any morphologically identifiable 
caveolae. In addition, Roussel et al. [171] found that very 
low levels of caveolin-1 were present in several lung cancer 
cells lines, although in most cases caveolin-2 was present at 
normal levels [172]. Caveolin-2 was shown to be unable to 
form caveolae in the absence of caveolin-1 [13], and in this 
case is also not transported out of the Golgi. The real func-
tion of caveolin-2 is still unknown but Webley et al. [173] 
suggest the evidence of its role as associated with the inclu-
sions of obligate intracellular pathogens. 
 Cassoni  et al. [174] also demonstrated an evident asso-
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membranous pattern of caveolin-1 expression. This evidence 
appears in brain tumor cells derived from 64 patients [174]. 
Different groups found caveolin-1 to be down-regulated in 
tumours derived from the ovary, breast and colon [162, 175]. 
In ovarian carcinoma cell lines this down-regulation required 
DNA methylation, and transfection of ovarian cancer cells 
with caveolin-1 decreased cell survival. While two carci-
noma cell lines did not down-regulate caveolin-1, they found 
the caveolin-1 in these cells to be phosphorylated on tyrosine 
14. Phosphorylation of caveolin-1 on tyrosine 14 (e.g., by 
Src) has been shown to stimulate anchorage-independent 
growth and cell migration [176]. In addition, Wiechen et al. 
[162] found that caveolin-1 was down-regulated in numerous 
human sarcomas, and interestingly found that treatment with 
an inhibitor of MEK potently up-regulated the expression of 
caveolin-1 in a fibrosarcoma cell line, while in this case 
interfering with methylation had little effect. 
Re-Expression of Caveolin-1 Inhibits Anchorage-
Independent Growth 
 Engelman  et al. [177] expressed caveolin-1 in v-Abl- and 
H-Ras (G12V)-transformed NIH 3T3 cells (which normally 
lack caveolin), and found that this abrogated the growth of 
these cells in soft agar. In v-Abl-transformed cells, caveolin-
1 expression also led to visible cell death. They also disco-
vered that expression of caveolin-1 inhibited H-Ras (G12V) 
and MAPK-dependent activation of the c-fos promoter (as 
determined by expression of a reporter gene attached to the 
promoter). Furthermore, transfection of F11 cells with caveo-
lin-1 lead to nucleosomal DNA fragmentation, a hallmark of 
apoptotic cell death. They suggest that re-expression of 
caveolin-1 inhibits the Ras/MAPK pathway and therefore 
inhibits anchorage-independent growth, and in the case of v-
Abl-transformed cells also causes cell death when colonies 
reach a certain size. 
 Zhang  et al. [88] found that motile mammary adenocar-
cinoma cells possessed reduced levels of caveolin-1, and that 
expression of caveolin-1 in these cells using an adenovirus 
vector blocked anchorage-independent growth. It also 
blocked EGF-stimulated Erk activation, lamellipod extension 
and cell migration. In a study by Fiucci et al. [178], trans-
fecting MCF-7 human breast carcinoma cells (which usually 
lack caveolin-1) with wild-type caveolin-1 inhibited proli-
feration, anchorage-independent growth and invasion of the 
extracellular matrix. It also prevented activation of Erk1/2 on 
contact with laminin. Lee et al. [179] found caveolin-1 to be 
down-regulated in several breast cancer cell lines, and found 
that re-expression of caveolin-1 inhibited growth. Finally, 
Bender et al. [180] demonstrated that re-expression of caveo-
lin-1 in colon carcinoma cell lines in most cases reduced 
their ability to form tumours in nude mice. However, in 30% 
of cases tumour formation was not reduced, and in these 
cases it was found that tumour formation resulted in the se-
lection of cells that did not contain caveolin-1. 
Targeted Down-Regulation of Caveolin-1 Promotes Cellu-
lar Transformation 
 Galbiati  et al. [87] used caveolin-1 antisense cDNA to 
down-regulate caveolin-1 in NIH 3T3 cells. These cells dis-
played altered morphology, anchorage-independent growth 
and loss of contact inhibition, all hallmarks of transforma-
tion, and were also capable of forming tumours in immuno-
deficient mice. It was shown that components of the p42/44 
MAPK cascade (MEK and Erk) were constitutively active in 
these cells, and this was necessary for maintenance of the 
transformed phenotype. In contrast, the p38 MAPK and JNK 
cascades were not affected. Jasmin et al. found that me-
chanical down-regulation of caveolin-1 in ischemic brain 
induce impaired angiogenesis and increased apoptotic cell 
death, whereas the phenotype of caveolin-2 absence was 
comparable to the wild-type [181]. 
Caveolin Knockout Mice 
  Caveolin-1 knockout mice were first reported in 2001, 
and a number of observations regarding these mice support a 
role for caveolae in suppressing growth. Razani et al. [182] 
found that embryonic fibroblasts derived from the knockouts 
proliferated twice as fast as the wild type cells, but this was 
not due to hyperactivation of the MAPK cascade. Zhao et al. 
also examined knockout mice and noted that they are com-
pleteli devoid of caveolae [183]. With the major transcytotic 
organelle absent, these mice were also predicted to have de-
creased vascular permeability [183, 184]. The further report 
of an increase in vascular permeability from Schubert et al. 
was therefore quite surprising [185]. 
 Lin  et al. [186] also presented evidence that in caveolin-1 
null mice there is an increased tumor permeability (defined 
by the extravasation of Evans blue and deposition of fibrino-
gen). Tumor permeability and angiogenesis are most likely 
interdependent, creating a positive feedback to support in-
creased tumor growth. The authors observed a hyper-
phosphorylation of VEGFR-2 that could be responsible for 
the increase in tumor permeability and angiogenesis through 
activation of several pathways. 
 Cohen  et al. [187] examined the hearts of caveolin-1 
knockouts and found that they possessed significantly 
thicker left ventricular walls than normal mice, as well as 
being significantly heavier overall. Closer examination re-
vealed cardiac myocyte hypertrophy (overgrowth) and fibro-
sis (formation of fibrous tissue). Erk1/2 was hyperactivated 
in heart tissue and in isolated cardiac fibroblasts. The levels 
of cyclin D1 (a regulator of the cell cycle) were not altered, 
although elevated levels of inducible and endothelial nitric 
oxide synthase may have contributed to the cardiac hyper-
trophy. In contrast, hyperactivation of Erk1/2 was not de-
tected in caveolin-2 knockout mice. 
 Lee  et al. [176] also examined caveolin-1 knockout mice, 
and found that although these mice failed to spontaneously 
develop mammary tumours, their mammary glands had an 
epithelial cell layer several cells thick. In addition, Capozza 
et al. [188] found that caveolin-1 knockout mice were more 
susceptible to skin carcinogenesis induced by a known car-
cinogen, 7,12-dimethylbenzanthracene (DMBA). 
 Williams  et al. [189] interbred caveolin-1 knockout mice 
with tumour-prone transgenic mice that normally develop 
multifocal mammary lesions. In tumour prone mice lacking 
caveolin-1, the frequency and size of the lesions were greatly 
increased, while this was not true for mice heterozygous for 
caveolin-1. However, in this case it was found that cyclin D1 
was up-regulated in the mammary lesions of the caveolin-1 
null mice as compared to the normal tumour prone mice, but 
no change in the activation state of the p42/44 MAPK cas-
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  Regarding caveolin-2 there are not really clear evidences 
about a possible role that it plays in cancer. In fact, lack of 
caveolin-2 does not affect the presence of caveolae, the ex-
pression of caveolin-1 and therefore of the receptors in-
volved in caveolae. But still Schubert et al. had evidence 
about age-related skeletal muscle abnormalities [190]. 
  Regarding caveolin-3 knock-out mice, the only evident 
phenotype is a disfunction in heart. Woodman et al. [191] 
had evidence of hyperactivation of p42/p44 MAPK (Erk1/2) 
that plays an important role as an effector of the cardiac hy-
pertrophic response. A cardiomyopathic phenotype was also 
present in the case of caveolin-1 and caveolin-3 double 
knock-out mice [192]. 
How is the Expression of Caveolin-1 Down-Regulated in 
Transformed Cells? 
  Several studies have investigated caveolin-1 down-
regulation in cancer, and hence provided further evidence 
that it acts as a tumour suppressor. Firstly, Engelman et al. 
[193] showed that caveolin-1 and caveolin-2 are localised in 
the q31.1 region of chromosome 7, a region that is com-
monly deleted in human cancers. In addition, caveolin-1 mu-
tations have now been detected: Hayashi et al. [194] identi-
fied heterozygous mutations in codon 132 (P132L) of caveo-
lin-1 in 16% of human primary breast tumours examined, 
while failing to observe this mutation in test subjects. Can-
cers harbouring the mutation were mainly invasive cancers. 
NIH 3T3 cells transfected with the caveolin-1 mutant 
showed disruption of the actin cytoskeleton and abnormal 
morphology, increased growth on soft agar, and constitutive 
activation of MAP kinases. Transfected cells also demons-
trated higher motility and invasive capacity than parental 
cells or cells transfected with wild type caveolin-1. Lee et al. 
[195] examined the P132L mutation further, and found that, 
in cells transfected with the mutant protein, the mutant was 
excluded from low density, Triton X-100 insoluble fractions. 
Immunofluorescence studies showed that the mutant caveo-
lin-1 was in fact retained at the Golgi complex. They also 
showed that the mutant protein acts in a dominant negative 
manner, causing wild-type protein to also be retained at the 
Golgi complex; this is an important observation, as the muta-
tion was generally found to be heterozygous in breast cancer 
cells [194]. 
  Hypermethylation of the caveolin-1 promoter may also 
be a mechanism by which its expression is altered in cancer. 
Methylation of CpG islands in the promoters of tumour sup-
pressor genes has been observed in transformed cells [196]. 
Engelman et al. found that CpG islands in the caveolin-1 
promoter were hypermethylated in two breast cancer cell 
lines that do not express caveolin-1. Cui et al. [197] also 
noted that caveolin-1 was hypermethylated at CpG islands in 
its promoter region in prostate cancer cells. However as yet it 
has not been proven that this methylation leads to down-
regulation of caveolin-1, and in fact some of the cancer cells 
studied by Cui et al. [197] actually had elevated levels of 
caveolin-1. Nevertheless, Wiechen et al. [198] did observe 
that the down-regulation of caveolin-1 in two ovarian cancer 
cell lines required DNA methylation. 
 Engelman  et al. [199] found that caveolin-1 was down-
regulated in cells transformed by mutationally activated Ras 
or Raf, and that treatment with a MEK inhibitor restored 
caveolin-1 mRNA and protein levels. They suggest therefore 
that caveolin-1 can be down-regulated by activation of the 
Ras/MAPK cascade. However, they also found that there 
were MAPK-independent pathways that could act to down-
regulate caveolin-1, for example in v-Src transformed cells. 
Control of expression appeared to be at the transcriptional 
level; indeed, transient transfection of CHO cells with acti-
vated Raf or Erk down-regulated caveolin-1 promoter acti-
vity. Overexpression of protein kinase A was also capable of 
down-regulating caveolin-1 expression. These results sug-
gest that caveolin-1 can be down-regulated by an oncogenic 
stimulus such as hyperactivation of the MAPK cascade. 
Engelman et al. [177] also demonstrated that caveolin-1 le-
vels could be regulated by an oncogenic stimulus: they used 
an NIH 3T3 cell line expressing a temperature-sensitive form 
of v-Abl. When the kinase was active, caveolin-1 was down-
regulated, but at non-permissive temperatures, when the 
kinase was inactive, caveolin-1 levels returned to those seen 
in normal cells. They also found that treatment with an in-
hibitor of MEK led to up-regulation of caveolin-1 (inhibitors 
of the p38 MAPK pathway, which involves different com-
ponents, did not affect caveolin-1 levels). Treatment with 
PDGF or FGF has also been shown to down-regulate caveo-
lin-1 expression in NIH 3T3 cells, and in the latter case at 
least this was at least partly due to activation of the p42/44 
MAPK cascade [87]. 
 Engelman  et al. [84] examined the relationship between 
ErbB2 (Neu, HER2) tyrosine kinase activity and caveolin-1 
expression. As mentioned previously, the gene encoding 
ErbB2 (Neu  or c-erbB2) is a proto-oncogene, the overex-
pression of which can cause cancer in humans [200]. In addi-
tion, mutationally activated forms of ErbB2 have been iden-
tified in rats and mice: e.g., oncogenic NeuT, the rat homo-
logue of ErbB2, has an activating mutation in the transmem-
brane region [200]. Engelman et al. [84] transfected fibro-
blast cell lines with various mutated forms of ErbB2 (includ-
ing NeuT) that are known to have oncogenic potential. 
Caveolin-1 mRNA and protein were down-regulated in these 
cells, but not in cells overexpressing wild-type ErbB2. The 
down-regulation of caveolin-1 by mutationally activated 
ErbB2 was partly dependent on the activation of the p42/44 
MAPK pathway by the receptor. In addition, caveolin-1 in-
hibited signal transduction from overexpressed wild-type 
ErbB2 and NeuT, and this inhibition was mediated by the 
scaffolding domain. In mammary tumours induced in mice 
by targeted overexpression of ErbB2, caveolin-1 was also 
down-regulated, as it was in tumours induced by overexpres-
sion of the downstream molecules Ras and Src. These results 
indicate a reciprocal interaction between ErbB2 and caveo-
lin-1. 
Caveolin-1 Levels are Not Always Reduced in Transformed 
Cells 
  In some tumours and tumour cell lines, it has been found 
that either caveolin-1 levels are unchanged compared to 
normal cells, or they are actually increased. For example, 
while Yang et al. [201] found caveolin-1 mRNA levels to be 
reduced in transformed NIH 3T3 cells, consistent with re-
sults discussed above, they also reported elevated caveolin-1 
mRNA and protein levels in prostate cancer cell lines de-
rived from metastases. The same was true for tissue samples: 
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which was up-regulated in primary tumours and further up-
regulated in metastatic tumours. Increased caveolin-1 ex-
pression was also detected in breast carcinoma tissue sam-
ples. In addition, Ho et al. [202] found that while caveolin-1 
levels were low in poorly invasive lung adenocarcinoma 
cells, caveolin-1 was abundant in highly invasive cells. 
Caveolin-1 levels were also low in tissue samples from pri-
mary lung adenocarcinomas, while caveolin-1 levels were 
generally higher in metastatic tumours. Furthermore, intro-
duction of caveolin-1 into poorly invasive cells induced filo-
podia formation and increased the invasive capacity of the 
cells. Taken together, these results suggest that high caveo-
lin-1 levels correlate with metastasis; this is also consistent 
with the findings of Bender et al. [180], who found that 
caveolin-1 was up-regulated in a metastatic cell line com-
pared to the parental cell line. 
 Lavie  et al. [203] discovered that caveolin-1 was up-
regulated in multidrug-resistant colon adenocarcinoma and 
breast carcinoma cells compared to the parental cell lines. 
The glycosphingolipid glucosylceramide, a constituent of 
caveolae, was also up-regulated in multidrug-resistant cell 
lines, as was caveolin-2. Consistent with these observations, 
the number of caveolae was increased in multidrug-resistant 
cells. The authors therefore suggest that caveolae play a role 
in the development of the multidrug-resistant phenotype. 
Consistent with results reported above, however, these cells 
were shown to have a reduced rate of proliferation. 
  Further results include those of Wiechen et al. [198], who 
also found caveolin-1 to be up-regulated in 11 out of 15 tu-
mour samples from the kidney, prostate and stomach, while 
Wiechen et al. [162] found caveolin-1 levels to be high in 
both normal mesenchymal tissues and benign mesenchymal 
tumours. Caveolin-1 has also been shown to be present in T-
cell leukaemia cell lines, though not present in normal T-
cells [204], and Hurlstone et al. [205] found caveolin-1 to be 
expressed in tumours derived from breast myoepithelium, as 
well as in normal epithelium. As discussed above, Podar et 
al. [127] found that caveolin-1 was expressed in multiple 
myeloma cells, and suggest that caveolae have a role in IGF-
1R signalling in these cells. However, their experiments do 
not distinguish between lipid rafts and caveolae. 
  Interestingly, although Fiucci et al. [178] found that ex-
pression of caveolin-1 in MCF-7 cells in general inhibited 
growth and invasion of the cancer cells, these cells were also 
resistant to anoikis (apoptosis induced by detachment from 
the extracellular matrix). Based on this observation, they 
suggest that where cancer cells express caveolin-1, they may 
have been positively selected due to its negative regulatory 
effects on apoptosis. 
  In summary, there is quite a large amount of evidence 
supporting a role for caveolin-1 as a tumour suppressor gene, 
including its location at a site commonly deleted in cancers, 
the identification of mutations in the caveolin-1 gene in 
some cancers, and its down-regulation in many tumours and 
tumour cell lines. It could be argued that the use of cell cul-
ture systems in many of the papers discussed makes the re-
sults less accurate, as conditions used in culture, such as the 
availability of cholesterol, could affect caveolin-1 expres-
sion. However, caveolin-1 has also been found to be down-
regulated in tumours themselves, and several independent 
studies have shown that the re-expression of caveolin-1 in 
transformed cells inhibits features of the transformed pheno-
type, such as anchorage-independent growth. Caveolin-1 
knockout mice also support the hypothesis, as they display 
hyperproliferative disorders and hyperactivation of the 
MAPK cascade, and are at greater risk from carcinogen-
induced tumorigenesis [188]. Although these mice do not 
spontaneously form tumours, knockouts of important cell 
cycle control agents, such as the cyclin-dependent kinase 
inhibitor p21, also do not form tumours [206]. Possibly 
compensatory proteins are involved, but it does not seem that 
caveolin-3 is one of these, as Razani et al. [182] found its 
levels unchanged in caveolin-1 knockouts. Fig. (3) illustrates 
how loss of caveolin-1 could lead to cellular transformation: 
caveolin-1 usually inhibits components of the MAPK cas-
cade and growth factor receptors, and so its loss leads to an 
increased availability of receptors and signalling molecules, 
causing hyperproliferation. However, although there is evi-
dence that this pathway plays a role in tumour suppressor 
activity [87] caveolin-1 also has other effects on the cell cy-
cle. For example, it has been shown to repress the transcrip-
tion of cyclin D1, which is required for cell cycle progres-
sion [207], and increased cyclin D1 expression was shown to 
be the main reason for the increased tumour formation in 
tumour prone caveolin-1 knockout mice [189]. In addition, 
caveolin-1 has been shown to cause cell cycle arrest at the 
G0/G1 phase via  a p53/p21-dependent mechanism [208]. 
Therefore it is likely that multiple functions contribute to the 
role of caveolin-1 as a tumour suppressor gene. 
  The ability of caveolin-1 to negatively regulate growth 
factor signalling pathways and cell cycle progression, and its 
identification as a candidate tumour suppressor, might sug-
gest the possibility of cancer treatments based on caveolin-1 
or its scaffolding domain. However, the fact that caveolin-1 
is up-regulated in some cancers, and especially in metastatic 
and multi-drug resistant cells, implies that caution would be 
required here, and clearly further work is required to enable a 
full understanding as to why caveolin-1 has these effects, 
and why it is down-regulated in some cancer cells and not 
others. 
CONCLUSIONS AND FUTURE PERSPECTIVES 
  The evidence presented in this article supports a role for 
lipid rafts and caveolae in the regulation of signalling from 
growth factor receptors. For many of the receptors it is not 
yet possible to say what the exact roles of each domain are, 
and further work is required to give a better understanding of 
the situation. However, caveolae are capable of inhibiting 
several receptors including the EGFR, TrkA and PDGFR, as 
well as components of the MAPK pathway (although possi-
bly not the PI3K/Akt pathway). In keeping with this, caveo-
lin-1 seems to act as a tumour suppressor in some cell types. 
In other cells, however, it is actually up-regulated upon 
transformation, and it also appears to be re-expressed in me-
tastatic tumours. This suggests that other factors are in-
volved, some of which are cell type specific. 
  A model was presented here to suggest that lipid rafts 
have an activatory role in EGFR signalling, forming signal-
ling platforms that allow efficient signal initiation and 
propagation. Such a role for lipid rafts is also possible in 
signalling by other receptors. Furthermore, this indicates a 
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gested that this might be the basis of a link between choles-
terol intake and prostate cancer; i.e. that increased choles-
terol increases raft size, stabilises EGFR signalling and in-
creases cell growth and survival. 
  The proposed involvement of lipid rafts and caveolae in 
cancer suggests the possibility of treatments that target these 
domains. However, a greater understanding of the reasons 
why caveolin-1 is up-regulated in some metastatic and drug-
resistant cells, and why it only acts as a tumour suppressor in 
some cancers, is first required. This would be necessary be-
fore the development of any treatment based on caveolin-1 
or its scaffolding domain, which inhibits components of the 
MAPK cascade. If such treatments were found to be possi-
ble, they would be very specific for certain cancers. The 
same is true for any attempt to treat cancer by cholesterol 
 
Fig. (3). Model for the role of caveolae in cellular transformation. A) In a normal cell, caveolin (hairpin structures) binds and inhibits 
receptors e.g., the EGFR and components of the MAPK cascade. B) In a transformed cell with low caveolin levels, more growth factor re-
ceptors and components of the MAPK cascade are free from the inhibitory effects, and this leads to increased proliferation. For clarity, not 
all components of the MAPK cascade are shown. Inactive molecules are shown as open ovals, whereas active molecules are depicted as 
filled ovals; EGF = epidermal growth factor; Erk = extracellular signal-regulated kinase. Lipid Rafts and Caveolae in Signaling by Growth Factor Receptors  The Open Biochemistry Journal, 2007, Volume 1    29 
depletion, and in this case in vivo studies are needed to de-
termine the exact link between cholesterol levels and cancer, 
and to confirm the hypothesis that increased cholesterol in 
the plasma membrane increases EGFR signalling. 
  It is clear to see that reports regarding the protein compo-
sition of lipid rafts and caveolae can often be contradictory. 
In many cases this is due in part to the fact that it is difficult 
to isolate these domains separately. In addition, there is the 
problem of detergent insolubility. In some cases, for example 
for the EGFR, proteins are found to be soluble in one deter-
gent such as Triton X-100, and insoluble in another such as 
Brij 58. As yet, the reasons for this are unclear: as explained 
above, it has been suggested that it may reflect a certain type 
of association of a protein with rafts, or possibly may indi-
cate the presence of distinct types of lipid raft. The latter 
possibility is intriguing, as it could be that different types of 
domain mediate signal transduction from different receptors, 
and this is worth further investigation. Regarding different 
types of caveolae, two forms, ‘deep’ and ‘shallow’ have been 
identified, as explained in the introductory section, and again 
more work is required to determine if they have functional 
differences. 
  In the future, experiments on lipid rafts and caveolae will 
be aided by the use of techniques which allow a more accu-
rate study of these domains [35]. At present, some of the 
major methods used include cholesterol depletion, which can 
have many effects on a cell, and the use of detergents, which 
have unpredictable effects on certain proteins. Because of 
their small size and their nature as integral components of 
cell membranes, lipid rafts and caveolae are still difficult to 
study, and this has been a hindrance to the study of their 
functions in signal transduction. 
ABBREVIATIONS 
CREB  =  cAMP response element-binding protein 
DMBA =  7,12-dimethylbenzanthracene 
EGFR  =  Epidermal growth factor receptor 
Erk  =  Extracellular signal-regulated kinase 
FGF  =  Fibroblast growth factor 
FRET  =  Fluorescence resonance energy transfer 
FRS2  =  Fibroblast growth factor receptor substrate 2 
GPI =  Glycosylphosphatidylinositol 
IGF-1R  =  Insulin-like growth factor-1 receptor 
IP3 =  Inositol  1,3,5-trisphosphate 
JNK  =  c-Jun N-terminal kinase 
MAPK  =  Mitogen-activated protein kinase 
MEK  =  Mitogen-activated Erk kinase 
mTOR  =  Mammalian target of rapamycin 
NGF  =  Nerve growth factor 
PA =  Phosphatidic  acid 
PDGFR  =  Platelet-derived growth factor receptor 
PDK1 =  3-phosphoinositide-dependent kinase-1 
PI3K =  Phosphatidylinostol  3-kinase 
PIP2 =  Phosphatidylinositol-4,5-bisphosphate 
PI(3,4)P2 = Phosphatidylinositol-3,4-bisphosphate 
PIP3 =  Phosphatidylinositol-3,4,5,-trisphosphate 
PKC  =  Protein kinase C 
PLC =  Phospholipase  C 
PLD =  Phospholipase  D 
S6K1  =  Ribosomal protein S6 kinase 1 
SH2  =  Src homology region 2 
SHIP =  SH2-containing  inositol-5-phosphatase 
Trk  =  Tyrosine kinase receptor 
uPAR  =  Urokinase-type plasminogen activator receptor 
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